Document is current
Any future updates will be listed below
-
Authors
Ntang, Emmaculate Yaah
Cunningham, Kyle T.
Singh, Shashi P. https://orcid.org/0000-0002-6029-8115
Ciancia, Claire
Sanders, Anna https://orcid.org/0009-0004-5829-4942
Lilla, Sergio https://orcid.org/0000-0003-3142-7640
Mukundan, Ananya
Ghogomu, Stephen M.
Hinck, Andrew P.
Maizels, Rick M. https://orcid.org/0000-0003-3216-1944
-
Funding
Funding for this research was provided by:
Wellcome Trust (219530)
Wellcome Trust (219530)
Wellcome Trust (219530)
Wellcome Trust (219530)
Wellcome Trust (219530)
Commonwealth Scholarship Commission (2871532)
U.S. Department of Health & Human Services | NIH | National Institute of General Medical Sciences (153915)
- License Information
-
More Information
Article History
Received: 21 February 2025
Revised: 7 November 2025
Accepted: 26 November 2025
First Online: 18 December 2025
Competing interests
: AH is a member of the scientific advisory board for TCGFB and is a licensee of intellectual property to Kalivir Immunotherapeutics. All other authors have no conflicts of interest to declare.
